Physician profile
Da Zhang
NPI 1750407037
$2,724.44
in general payments reported to CMS, 2019-2025
20 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.63 · 2022: $162 · 2023: $1,004 · 2024: $1,301 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,515.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $610.27 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $484.52 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $349.07 | 2023-2025 | |
| Glaxosmithkline, LLC. | $269.40 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $237.45 | 2023-2024 | Freestyle Libre 3, Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.48 | 2023-2024 | Xifaxan |
| Astellas Pharma US INC | $122.13 | 2023-2025 | Veozah |
| Amgen INC. | $115.24 | 2019-2024 | Repatha, Otezla |
| Stryker Corporation | $66.26 | 2025 | Clottriever Bold Catheter |
| Lilly USA, LLC | $60.96 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $49.73 | 2023-2024 | Airsupra, Breztri, Farxiga |
| Idorsia Pharmaceuticals US INC | $40.74 | 2022-2023 | Quviviq |
| Dexcom, INC. | $40.55 | 2023-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $31.79 | 2024 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $23.27 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $22.68 | 2024 | Slynd |
| Daiichi Sankyo INC. | $21.64 | 2024 | Injectafer |
| Merck Sharp & Dohme LLC | $17.66 | 2023 | Belsomra |
| Mylan Specialty L.P. | $16.30 | 2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $15.30 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Da Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.